218 related articles for article (PubMed ID: 24590651)
1. To treat or not to treat, that is the question: the role of bone-targeted therapy in metastatic prostate cancer.
Higano CS
J Clin Oncol; 2014 Apr; 32(11):1107-11. PubMed ID: 24590651
[TBL] [Abstract][Full Text] [Related]
2. Incorporating Androgen Deprivation With Dose-Escalated External-Beam Radiotherapy for Prostate Cancer.
Dosoretz AP; Yu JB
J Clin Oncol; 2016 May; 34(15):1718-22. PubMed ID: 27001587
[TBL] [Abstract][Full Text] [Related]
3. [Metastatic prostate cancer complicated with chronic disseminated intravascular coagulopathy causing acute renal failure, mimicking thrombotic thrombocytopenic purpura and hemolytic uremic syndrome: pathomechanism, differential diagnosis and therapy related to a case].
Deme D; Ragán M; Kalmár K; Kovács L; Varga E; Varga T; Rakonczai E
Magy Onkol; 2010 Dec; 54(4):351-7. PubMed ID: 21163766
[TBL] [Abstract][Full Text] [Related]
4. Clinico-pathologic characterisation of metastatic prostate cancer in the Radiotherapy and Oncology Department, Ahmadu Bello University Teaching Hospital, Zaria-Nigeria: 2006-2009.
Adewuyi SA; Mbibu NH; Samaila MO; Ketiku KK; Durosinmi-Etti FA
Niger Postgrad Med J; 2013 Mar; 20(1):45-51. PubMed ID: 23661210
[TBL] [Abstract][Full Text] [Related]
5. Prostate cancer presenting with normal serum PSA levels and boney metastases treated with zoledronic acid.
Mystakidou K; Katsouda E; Parpa E; Vlahos L
J Pain Palliat Care Pharmacother; 2005; 19(3):41-5. PubMed ID: 16219610
[TBL] [Abstract][Full Text] [Related]
6. Implications of androgen-deprivation therapy in patients with prostate cancer: A case study.
Doyle-Lindrud S
Clin J Oncol Nurs; 2006 Oct; 10(5):565-6. PubMed ID: 17063610
[TBL] [Abstract][Full Text] [Related]
7. Optimization of Risk Stratification in Localized Prostate Cancer.
Morgans AK
J Clin Oncol; 2018 Feb; 36(6):528-532. PubMed ID: 29303624
[TBL] [Abstract][Full Text] [Related]
8. Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy.
Zumsteg ZS; Daskivich TJ; Sandler HM
J Clin Oncol; 2016 Nov; 34(32):3829-3833. PubMed ID: 27573664
[TBL] [Abstract][Full Text] [Related]
9. Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy.
Miyamoto S; Ito K; Miyakubo M; Suzuki R; Yamamoto T; Suzuki K; Suzuki K; Yamanaka H
Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):75-86. PubMed ID: 21986985
[TBL] [Abstract][Full Text] [Related]
10. Additive effect of zoledronic acid on serum prostate-specific antigen changes for hormone-sensitive prostate cancer patients with bone metastasis treated by combined androgen blockade.
Kamiya N; Suzuki H; Endo T; Takano M; Yano M; Naoi M; Nishimi D; Kawamura K; Imamoto T; Ichikawa T
Int J Urol; 2012 Feb; 19(2):169-73. PubMed ID: 22126137
[TBL] [Abstract][Full Text] [Related]
11. Preventing bone complications in prostate cancer.
Bishr M; Saad F
Curr Opin Support Palliat Care; 2012 Sep; 6(3):299-303. PubMed ID: 22871982
[TBL] [Abstract][Full Text] [Related]
12. Prostate Cancer Radiotherapy: An Evolving Paradigm.
Catton CN; Lukka H; Martin J
J Clin Oncol; 2018 Oct; 36(29):2909-2913. PubMed ID: 30138084
[TBL] [Abstract][Full Text] [Related]
13. A case of metastatic cancer with markedly elevated PSA level that was not detected by repeat prostate biopsy.
Iwamura H; Hatakeyama S; Tanaka Y; Tanaka T; Tokui N; Yamamoto H; Imai A; Yoneyama T; Hashimoto Y; Koie T; Yoshikawa K; Ohyama C
BMC Res Notes; 2014 Jan; 7():64. PubMed ID: 24476098
[TBL] [Abstract][Full Text] [Related]
14. [A case of prostate cancer associated with osteolytic bone metastases].
Migita T; Maeda K; Ogata N
Hinyokika Kiyo; 1999 May; 45(5):371-4. PubMed ID: 10410324
[TBL] [Abstract][Full Text] [Related]
15. Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician.
Higano CS
Urol Clin North Am; 2004 May; 31(2):331-52. PubMed ID: 15123412
[TBL] [Abstract][Full Text] [Related]
16. Nadir PSA level and time to PSA nadir following primary androgen deprivation therapy are the early survival predictors for prostate cancer patients with bone metastasis.
Sasaki T; Onishi T; Hoshina A
Prostate Cancer Prostatic Dis; 2011 Sep; 14(3):248-52. PubMed ID: 21502970
[TBL] [Abstract][Full Text] [Related]
17. Should the denosumab metastasis prevention trial change practice for men with nonmetastatic prostate cancer?
Saylor PJ; Michaelson MD
Oncologist; 2012; 17(2):288-90. PubMed ID: 22267850
[TBL] [Abstract][Full Text] [Related]
18. New and emerging therapies for bone metastases in genitourinary cancers.
Saylor PJ; Armstrong AJ; Fizazi K; Freedland S; Saad F; Smith MR; Tombal B; Pienta K
Eur Urol; 2013 Feb; 63(2):309-20. PubMed ID: 23201471
[TBL] [Abstract][Full Text] [Related]
19. Skeletal-related events in prostate cancer.
Smith MR
Clin Adv Hematol Oncol; 2012 Aug; 10(8):535-6. PubMed ID: 23073052
[No Abstract] [Full Text] [Related]
20. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
